Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
about
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsAntipsychotic-induced hyperprolactinemiaZiprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.Ziprasidone in the treatment of mania in bipolar disorder.Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.Ziprasidone: a novel psychotropic with unique properties.Switching antipsychotics: an updated review with a focus on quetiapine.Interventions for the metabolic syndrome in schizophrenia: a reviewThe metabolic effects of antipsychotic medications.Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.Evidence review and clinical guidance for the use of ziprasidone in Canada.Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.Schizophrenia, obesity, and antipsychotic medications: what can we do?Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone.Atypical antipsychotic tolerability and switching strategies in bipolar disorder.Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.Switching to ziprasidone in the clinical practice setting: an open-label study.The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study.
P2860
Q24235450-1380EC62-B7DF-425B-9C37-4687F301DCEAQ28305237-1934FBBD-36D0-4D2D-9F15-84798961BCCFQ30984472-E85D0634-7553-4BF1-B064-6B7338B28A86Q33235110-CAA1E19C-CAD2-4298-84E1-FA062AA031CEQ34315836-CA3C85CC-2EF2-4349-BB8E-E0D906FE464DQ34413977-8DBB5F10-1D60-459D-AD1E-6FD694D5E614Q34486175-97B884DE-2474-4987-9FB7-50F972C2EB15Q34653803-2D861DBF-790B-40FB-871D-56FB616748D9Q34966022-CC479E1F-B672-4550-BDF9-417EFC8F2292Q35031175-D795B8B7-C09B-45C7-8B30-439C2C597C57Q35369968-3C42899C-7A20-4380-9ADF-5597210135FCQ36107060-39F22B99-2A17-4812-BEEA-21F03B4DC72FQ36276541-0FA2B330-38CE-462D-9977-3521E2D0942EQ36401248-6882DA07-A4E6-44EF-BE02-6C59C42F43C7Q36577856-30411AB9-8EDC-4694-8840-0442A9F3EF18Q36577866-A8780F39-5AC3-45A4-AC4A-4519A0884026Q36588607-02779146-508A-412A-B860-1DB06B816E5FQ36700337-F8AED45D-3429-4171-8385-D80BA59048F6Q37039179-115F04D9-FACB-45D6-84A6-C5E6F260C2E9Q37160453-B91E0D29-CB18-416B-A853-6ACC3A25A67BQ37161980-4F96DC19-C185-408E-8E7A-0707159AA095Q37172865-0A568FD0-6ED1-428C-B181-2830E0E80C64Q37226376-0ABEE123-03E2-498C-A7BE-12A151C44C1BQ37281587-2F962453-7CFF-43A8-BCAF-8BEFE99B1DFCQ37561314-5EA47275-8B9D-450E-B5B6-CD112B35EDDAQ37781370-E69535DC-B898-415D-A7EF-4FC33D86467EQ38005470-EE5145AC-18E5-4F52-BC63-4BAFE983550DQ38119865-6A8A90F8-79C8-4E76-80FB-2A6FD15C7F64Q40910264-E1E2C904-48FA-469D-8983-5ACC97A4283DQ42615483-F7DB6F05-54FB-460B-BFB8-8B7346B5D590Q42990103-831C6D63-CCEE-44FD-8E4B-2ACFBCB594E9Q46533468-A6CCEB01-AB0F-4A86-9AAE-CB769A08C35EQ46727324-A9E8A3CA-41C7-4014-8718-4579647F10ACQ47279555-64BAAFBB-4F44-4F78-94A5-3EC6D3EE1543Q50737699-5FBC5734-4F43-49D7-8240-B0FDDCD56F44Q50773348-594BAB14-FDE4-4417-9AA5-DA4AFA902B75Q51366559-3260AD89-4CA5-4FED-9F88-A710DBE5D30FQ55423163-14315FD3-2E99-44B7-902F-4CFBF77A9D21
P2860
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Improvement in indices of heal ...... renia switched to ziprasidone.
@ast
Improvement in indices of heal ...... renia switched to ziprasidone.
@en
type
label
Improvement in indices of heal ...... renia switched to ziprasidone.
@ast
Improvement in indices of heal ...... renia switched to ziprasidone.
@en
prefLabel
Improvement in indices of heal ...... renia switched to ziprasidone.
@ast
Improvement in indices of heal ...... renia switched to ziprasidone.
@en
P2093
P1476
Improvement in indices of heal ...... renia switched to ziprasidone.
@en
P2093
David G Daniel
George Simpson
Peter J Weiden
Steven J Romano
P304
P356
10.1097/01.JCP.0000095347.32154.08
P407
P577
2003-12-01T00:00:00Z